Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ugur Coskun

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Tumori|September 18, 2010
Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancerAli Osman Kaya, Suleyman Buyukberber, Faysal Dane, et al.
Onkologie|December 5, 2012
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experienceBulent Cetin, Mustafa Benekli, Berna Oksuzoglu, et al.
Oncology Letters|October 19, 2013
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experienceUmut Kefeli, Mustafa Benekli, Alper Sevinc, et al.
Journal of Cancer Research and Clinical Oncology|August 11, 2012
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancerOnder Tonyali, Ugur Coskun, Nur Sener, et al.
Onkologie|October 11, 2013
Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumabOnder Tonyali, Ugur Coskun, Nur Sener, et al.
Hepato-Gastroenterology|November 21, 2012
Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experienceUmut Kefeli, Suleyman Buyuberber, Murat Akyol, et al.
Breast (Edinburgh, Scotland)|January 24, 2016
Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumabOnder Tonyali, Ugur Coskun, Sinemis Yuksel, et al.
Journal of Cancer Research and Clinical Oncology|February 13, 2013
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)Umut Demirci, Gulnihal Tufan, Bilge Aktas, et al.
Journal of Cancer Research and Clinical Oncology|December 3, 2013
Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncologyOzge Gumusay, Ugur Coskun, Tülay Akman, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|November 22, 2012
Clinicopathological features in bilateral breast cancerMeltem Baykara, Selcuk Cemil Ozturk, Suleyman Buyukberber, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Tumori|September 18, 2010
Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancerAli Osman Kaya, Suleyman Buyukberber, Faysal Dane, et al.
Onkologie|December 5, 2012
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experienceBulent Cetin, Mustafa Benekli, Berna Oksuzoglu, et al.
Oncology Letters|October 19, 2013
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experienceUmut Kefeli, Mustafa Benekli, Alper Sevinc, et al.
Journal of Cancer Research and Clinical Oncology|August 11, 2012
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancerOnder Tonyali, Ugur Coskun, Nur Sener, et al.
Onkologie|October 11, 2013
Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumabOnder Tonyali, Ugur Coskun, Nur Sener, et al.
Hepato-Gastroenterology|November 21, 2012
Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experienceUmut Kefeli, Suleyman Buyuberber, Murat Akyol, et al.
Breast (Edinburgh, Scotland)|January 24, 2016
Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumabOnder Tonyali, Ugur Coskun, Sinemis Yuksel, et al.
Journal of Cancer Research and Clinical Oncology|February 13, 2013
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)Umut Demirci, Gulnihal Tufan, Bilge Aktas, et al.
Journal of Cancer Research and Clinical Oncology|December 3, 2013
Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncologyOzge Gumusay, Ugur Coskun, Tülay Akman, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|November 22, 2012
Clinicopathological features in bilateral breast cancerMeltem Baykara, Selcuk Cemil Ozturk, Suleyman Buyukberber, et al.
Pageof 14